Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Nature Communications

Volumn 7, Issue , 2016, Pages

  Chabon, Jacob J ^a,b   Simmons, Andrew D ^c   Lovejoy, Alexander F ^a,b   Esfahani, Mohammad S ^a,b   Newman, Aaron M ^a,b   Haringsma, Henry J ^c   Kurtz, David M ^a,d   Stehr, Henning ^a,b   Scherer, Florian ^a,b   Karlovich, Chris A ^c   Harding, Thomas C ^c   Durkin, Kathleen A ^e   Otterson, Gregory A ^f   Purcell, W Thomas ^g   Camidge, D Ross ^g   Goldman, Jonathan W ^h   Sequist, Lecia V ⁱ   Piotrowska, Zofia ⁱ   Wakelee, Heather A ^a   Neal, Joel W ^a   Alizadeh, Ash A ^a,b   Diehn, Maximilian ^a,b,j   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c Clovis Oncology Inc   (United States)

^d Stanford University   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; ROCILETINIB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AMPLIFICATION; CANCER; DNA; HETEROGENEITY; INHIBITOR; MUTATION; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DETERMINATION; DNA FINGERPRINTING; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE DOSAGE; GENETIC HETEROGENEITY; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY;

ACRYLAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974625022     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11815     Document Type: Article

References (66)

1. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
2. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
3. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
4. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
5. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
6. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
7. Miller, V. A. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012).
8. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 0225-0235 (2005).
9. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
10. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med 3, 75ra26 (2011).
11. Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
12. Walter, A. O. et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov. 3, 1404-1415 (2013).
13. Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046-1061 (2014).
14. Jänne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699 (2015).
15. Sequist, L. V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015).
16. Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 1-5 (2015).
17. Piotrowska, Z. et al. Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-positive cancers with a third generation EGFR inhibitor. Cancer Discov. 5, 713-722 (2015).
18. Planchard, D. et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 26, 2073-2078 (2015).
19. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
20. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
21. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
22. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
23. Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109, E2127-E2133 (2012).
24. Suda, K. et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 16, 5489-5498 (2010).
25. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
26. Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
27. Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10, 472-484 (2013).
28. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).
29. Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol 34, 547-555 (2016).
30. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
31. Bettegowda, C. et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
32. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
33. Ercan, D. et al. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors. Clin. Cancer Res. 21, 3913-3923 (2015).
34. Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924-3933 (2015).
35. Chong, C. R., Jänne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013).
36. Ohashi, K., Maruvka, Y. E., Michor, F., Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013).
37. Eberlein, C. A. et al. Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 75, 2489-2500 (2015).
38. Sholl, L. M. et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma. J. Thorac. Oncol. 10, 768-777 (2015).
39. Benesova, L., Minarik, M., Jancarikova, D., Belsanova, B., Pesek, M. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res. 30, 1667-1671 (2010).
40. Sun, L. et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J. Exp. Clin. Cancer Res. 30, 30 (2011).
41. Takeda, M. et al. De novo resistance to epidermal growth factor receptortyrosine inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J. Thorac. Oncol. 5, 399-400 (2010).
42. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
43. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
44. Sequist, L. V. et al. Osimertinib responses after disease progression in patients who had been receiving rociletinib. JAMA Oncol. 2, 17-19 (2015).
45. Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
46. Friboulet, L. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4, 662-673 (2014).
47. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104, 20932-20937 (2007).
48. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
49. Marchetti, A. et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J. Thorac. Oncol. 10, 1437-1443 (2015).
50. Mok, T. et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21, 3196-3203 (2015).
51. Oxnard, G. R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20, 1698-1705 (2014).
52. Sorensen, B. S. et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120, 3896-3901 (2014).
53. Taniguchi, K. et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808-7815 (2011).
54. Thress, K. S. et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90, 509-515 (2015).
55. Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655 (2005).
56. Buckingham, L. E. et al. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J. Thorac. Oncol. 2, 414-422 (2007).
57. Takano, T. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829-6837 (2005).
58. Hirsch, F. R. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034-5042 (2006).
59. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Preprint at http://biorxiv.org/content/early/2015/10/30/030338 (2015).
60. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-307 (2012).
61. Schrödinger Release 2015-2: Prime, version 4.0 (Schrödinger, LLC, New York, NY, 2015).
62. Jacobson, M. P. et al. A hierarchical approach to all-atom protein loop prediction. Proteins 55, 351-367 (2004).
63. Schrödinger Release 2015-2: Desmond Molecular Dynamics System, version 4.2 (D. E. Shaw Research, New York, NY, 2015. Maestro-Desmond Interoperability Tools, version 4.2 (Schrödinger, New York, NY, 2015).
64. Bowers, K. et al. in Proceedings of the 2006 ACM/IEEE Conference of Supercomputing 43-43 (New York, 2006).
65. Sah, S. et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med. 5, 77 (2013).
66. Hadd, A. G. et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J. Mol. Diagn. 15, 234-247 (2013).